Search Results for "Where To Buy Pirfenidone"

09:21 EST 29th January 2015 | BioPortfolio

Matching Channels

None

Matching News

Roche’s Pirfenidone Bet Validates China Venture

China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as val...

FDA Approves Esbriet (pirfenidone) for Idiopathic Pulmonary Fibrosis

October 15, 2014 -- The U.S. Food and Drug Administration today approved Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is a condition i...

Genoa gets orphan-drug status for pirfenidone to treat idiopathic pulmonary fibrosis

Genoa Pharmaceuticals has received orphan-drug designation from the US Food and Drug Administration (FDA) for pirfenidone to use in their lead program - inhaled GP-101 for the treatment of Idiopathic ...

FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States

Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) in the United States. IPF is a fatal di...

Real world data supports InterMune's IPF drug

New pooled analyses of data from phase 3 trials presented by InterMune shows that its treatment for idiopathic pulmonary fibrosis (IPF) pirfenidone has long-lasting benefits for patients.The data come...

Roche buying InterMune for $8.3B

Roche (SIX:ROG; OTCQX:RHHBY) will acquire InterMune Inc. (NASDAQ:ITMN) for $74 per share, or about $8.3 billion in cash. The offer is a 63% premium to InterMune's $45.49 closing price on Aug. 12, befo...

InterMune boosted by pirfenidone data

InterMune boosted by pirfenidone data

Human medicines European public assessment report (EPAR): Esbriet, pirfenidone, Revision: 9, Authorised

Matching PubMed Articles

Pirfenidone attenuates the IL-1β-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.

Purpose:This study aimed to investigate the effect of pirfenidone on the interleukin (IL)-1β-induced hyaluronic acid (HA) increase in orbital fibroblasts from patients with thyroid-associated ophthal...

Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS.

A rapid, sensitive and selective ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of pi...

Pirfenidone: an update on clinical trial data and insights from everyday practice.

Pirfenidone is an orally active, small molecule that inhibits synthesis of profibrotic and inflammatory mediators. It was approved for the treatment of adults with mild-to-moderate idiopathic pulmonar...

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events.

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free ...

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Pirfenidone, an oral anti-inflammatory, antifibrotic agent with activity in idiopathic pulmonary fibrosis, may mediate anti-tumor activity in neurofibromatosis type 1 (NF1) and plexiform neurofibromas...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement